Accelerated tryptophan degradation predicts poor survival in trauma and sepsis patients

International Journal of Tryptophan Research

Volumn 3, Issue 1, 2010, Pages 61-67

  Ploder, Martin ^a   Spittler, Andreas ^a   Kurz, Katharina ^c   Neurauter, Gabriele ^c   Pelinka, Linda E ^b   Roth, Erich ^a   Fuchs, Dietmar ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b FEDERAL RESEARCH AND TRAINING CENTRE FOR FORESTS   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

IDO; Kynurenine; Outcome; Sepsis; Trauma; Tryptophan degradation

Indexed keywords

EID: 84859877054     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/ijtr.s3983     Document Type: Article

References (30)

1. WHO. World Health Statistics 2009. http://www.who.int/whosis/whostat/EN_WHS09_Full.pdf
2. Baker SP, O'Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-96.
3. Grimminger F, Mayer K, Seeger W. Is there a reliable immunotherapy in infection? Internist (Berl). 1997;38:541-52.
4. Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12:595-601.
5. Majetschak M, Flach R, Heukamp T, et al. Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma. 1997;43:880-7.
6. Flach R, Majetschak M, Heukamp T, et al. Relation of ex vivo stimulated blood cytokine synthesis to post-traumatic sepsis. Cytokine. 1999;11(2):173-8.
7. Ploder M, Pelinka L, Schmuckenschlager C, et al. Lipopolysaccharideinduced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 2006;25:129-34.
8. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett. 1989;23: 103-8.
9. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987;41:273-80.
10. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A. 1984;81:908-12.
11. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516-22.
12. Pellegrin K, Neurauter G, Wirleitner B, Fleming AW, Peterson VM, Fuchs D. Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock. 2005;23:209-15.
13. Ploder M, Spittler A, Schroecksnadel K, et al. Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors. Clin Sci (Lond). 2009;116:593-8.
14. Martin C, Saux P, Mege JL, Perrin G, Papazian L, Gouin F. Prognostic values of serum cytokines in septic shock. Intensive Care Med. 1994;20:272-7.
15. Svoboda P, Kantorova I, Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma. 1994; 36:336-40.
16. Strohmaier W, Redl H, Schlag G, Inthorn D. D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med. 1987;15:757-60.
17. Hensler T, Sauerland S, Lefering R, et al. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock. 2003;20:420-6.
18. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler. 1989;370:1063-9.
19. Fuchs D, Moeller AA, Reibnegger G, et al. Increased endogenous interferongamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett. 1991;28: 207-11.
20. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferongamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003;(10):1581-91.
21. Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren's syndrome. Clin Exp Immunol. 2005;142:155-61.
22. Pertovaara M, Raitala A, Juonala M, et al. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007;148:106-11.
23. Ploder M, Spittler A, Schroecksnadel K, et al. Accelerated tryptophan degradation in trauma and sepsis patients is related to pro-inflammatory response and to the diminished in vitro response of monocytes. Pteridines. 2009;19:54-61.
24. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43:2424-6.
25. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem. 2002;48:579-81.
26. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-74.
27. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069-77.
28. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003;24:242-8.
29. Fuchs D, Widner B, Jurika D, Rudzite V. Similarity between the action of pteridines and tryptophan metabolites on lipid metabolism. Pteridines. 1999;10:133-40.
30. Weiss G, Diez-Ruiz A, Murr C, Theurl I, Fuchs D. Tryptophan Metabolites as Scavengers of Reactive Oxygen and Chlorine Species. Pteridines. 2002;13:140-4.